Burstein Jennifer 4

What Happened

• Jennifer Burstein, a director of Stoke Therapeutics (STOK), received a grant of derivative securities covering 17,786 shares on June 3, 2026. The filing shows an acquisition price of $0.00 (no cash paid at grant), with a reported value of $0. This is an award/option grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-03; Filing date: 2026-06-05 (filed within the normal two-business-day window).
• Reported price: $0.00 per share at grant; total reported value $0.
• Shares acquired via the derivative award: 17,786 underlying shares.
• Shares owned after transaction: Not specified in the provided Form 4 excerpt.
• Vesting note (footnote): The option vests in full on the earlier of (i) June 3, 2027 or (ii) the issuer’s next annual meeting, subject to Burstein’s continued service.
• Filing type: Derivative award (A). No indication in this filing of immediate exercise or sale.

Context

• This grant is a compensated equity award (an option) that will only convert to exercisable shares according to the vesting schedule. It is not an immediate cash purchase or sale, and any future exercise or sale would generate separate Form 4 filings. Such awards are common for aligning executive/director incentives but do not, by themselves, indicate an immediate market view.